ALISON KRASKA: Open Payments
NPI 1801652342 · DANBURY, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,555 in 114 payments from 18 companies in 2025. Trend: 2023 $0 · 2024 $889 · 2025 $2,555
Food & beverage: $2,555
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 19 | $655 |
| Otsuka America Pharmaceutical, Inc. | 19 | $254 |
| Neurocrine BioSciences, Inc. | 10 | $221 |
| E.R. Squibb & Sons, L.L.C. | 10 | $180 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 8 | $179 |
| Alkermes, Inc. | 8 | $152 |
| Vanda Pharmaceuticals Inc. | 6 | $147 |
| Axsome Therapeutics, Inc. | 8 | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $125 |
| Janssen Pharmaceuticals, Inc | 4 | $122 |
Products named: VRAYLAR, INGREZZA, REXULTI, COBENFY, CAPLYTA, FANAPT, ARISTADA, TRINTELLIX.
Industry payments across CT — which companies pay providers there.
